Aikido Pharma Announces Information on KPC-34 Which Was Developed at the Wake Forest School of Medicine

Aikido Pharma Inc is a biotechnology development company working to develop a diverse portfolio of early and mid-stage small-molecule anti-cancer therapeutics. Our diverse pipeline of therapeutics includes therapies for prostate, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). For more information, get in touch with Aikido Pharma Inc by calling us at 212-745-1373.  

Learn about our KPC-34 drug that has been developed at Wake Forest School of Medicine for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). 70% of all AML patients are over the age of 60 and only 6.6% of patients are still alive 5 years after diagnosis. Gemcitabine and Cytarabine are the backbone of AML and ALL therapy, but life expectancy is poor and relapses are much harder to treat.

Cytarabine (Ara-C) has been a major drug for acute myeloid leukemia (AML) treatment for more than three decades. But KPC34 has shown superior results when tested against Cytarabine.

For more information about our KPC-34 drug or to see some of the results from trials, please visit our website for additional infographics. Get in touch with Aikido Pharma Inc by calling us at 212-745-1373.